AI Article Synopsis
- - Passive immunization using nirsevimab effectively shields infants from severe respiratory syncytial virus (RSV) disease.
- - This method provides protection without negatively affecting the infants' natural immune response to RSV infections.
- - Nirsevimab represents a promising preventive treatment for safeguarding vulnerable infants against a potentially serious respiratory illness.
Article Abstract
Passive immunization with nirsevimab protects infants from severe RSV disease without impairing the immune response to natural infection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528347 | PMC |
| http://dx.doi.org/10.1126/sciimmunol.adi8764 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Respiratory syncytial virus immunoprophylaxis: Novel opportunities and a call for equity.
J Med Virol
February 2024
Biosystems and Environmental Enginering Research Group, Harare, Zimbabwe.
With the approval of the first vaccines against respiratory syncytial virus (RSV) and a novel RSV-neutralizing antibody, 2023 has been perceived as a game-changing year in preventing severe outcomes of RSV infections in infants and the elderly. However, the costs of these pharmaceuticals are high, while RSV disproportionately impacts populations of low-to-middle-income regions, which may continue to suffer from a lack of pharmaceutical measures for RSV prevention under health and socioeconomic disparities. This paper presents an overview of the characteristics, clinical results, and approval status of various RSV vaccines and anti-RSV antibodies.
View Article and Find Full Text PDFPerspective: the potential of wastewater-based surveillance as an economically feasible game changer in reducing the global burden of pediatric respiratory syncytial virus infection.
Front Public Health
January 2024
Department of Civil Engineering, University of Ottawa, Ottawa, ON, Canada.
Respiratory syncytial virus (RSV) is the leading viral cause of childhood bronchiolitis and pneumonia causing over 3 million hospitalizations and 100,000 deaths in children under 5 years of age annually. Wastewater-based surveillance (WBS) has proven an effective early warning system for high-consequence pathogens, including SARS-CoV-2, polio, mpox, and influenza, but has yet to be fully leveraged for RSV surveillance. A model predicated on the Canadian province of Ontario demonstrates that implementation of a WBS system can potentially result in significant cost savings and clinical benefits when guiding an RSV preventive program with a long-acting monoclonal antibody.
View Article and Find Full Text PDFThe Next Generation COVID-19 Antiviral; Niclosamide-Based Inorganic Nanohybrid System Kills SARS-CoV-2.
Small
September 2024
Intelligent Nanohybrid Materials Laboratory (INML), Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan, 31116, Republic of Korea.
The coronavirus disease 2019 (COVID-19) pandemic is a serious global threat with surging new variants of concern. Although global vaccinations have slowed the pandemic, their longevity is still unknown. Therefore, new orally administrable antiviral agents are highly demanded.
View Article and Find Full Text PDFGame over for RSV?
Sci Immunol
June 2023
Department of Immnobiology and Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.
Article Synopsis
- - Passive immunization using nirsevimab effectively shields infants from severe respiratory syncytial virus (RSV) disease.
- - This method provides protection without negatively affecting the infants' natural immune response to RSV infections.
- - Nirsevimab represents a promising preventive treatment for safeguarding vulnerable infants against a potentially serious respiratory illness.
Changes in endemic patterns of respiratory syncytial virus infection in pediatric patients under the pressure of nonpharmaceutical interventions for COVID-19 in Beijing, China.
J Med Virol
January 2023
Laboratory of Virology, Beijing Key Laboratory of Etiology of Viral Diseases in Children, Capital Institute of Pediatrics, Beijing, China.
Article Synopsis
- Nonpharmaceutical interventions (NPIs) were implemented in Beijing starting January 24, 2020, to control COVID-19, impacting the respiratory syncytial virus (RSV) dynamics in the region.
- Analysis of respiratory samples from children revealed a significant decline in RSV positive rates following the NPIs, dropping from 31.93% in January 2020 to as low as 1% by March.
- The study noted a shift in RSV subtypes, with RSV-A becoming dominant, and a reduced incidence of severe pneumonia cases among children after the NPIs were introduced.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!